- Annovis Bio forms part of an exclusive league of clinical-stage biotechs working on both Alzheimer's and Parkinson’s diseases.
- The stock's abruptly fluctuating path, influenced by results of clinical trials deserves to be analyzed.
- The analysis shows that much-publicized positive results caused astronomical upsides, but more recent confusing data led to a vertiginous plunge.
- Still, the knowledge required for research in neurodegenerative brain conditions is not currently within the area of expertise of most biotechs in a context where the number of people afflicted is on the rise.
- Therefore, equipped with sufficient finances to complete its Phase 2 trials, Annovis should still form part of your watch-list, but avoid buying for the time being as negative market sentiment prevails.
For further details see:
Annovis Bio: Should Still Be On Your Watchlist